Preliminary evidence that caffeine improves attention in multiple sclerosis.

Area of Science:

• Neuroscience
• Cognitive Psychology
• Neurology

Background:

• Multiple sclerosis (MS) often involves cognitive impairments, particularly affecting attention.
• Currently, no FDA-approved medications specifically target cognitive enhancement in MS.
• Caffeine is a widely consumed stimulant with known effects on alertness and attention.

Purpose of the Study:

• To investigate the potential of caffeine as a cognitive enhancer in individuals with multiple sclerosis.
• To assess caffeine's effects on specific attentional functions in MS patients.

Main Methods:

• A double-blind, placebo-controlled study design was employed.
• Participants with MS underwent attentional testing across four sessions.
• Cognitive performance was measured using choice reaction time, Stroop task, and Rapid Serial Visual Presentation (RSVP) tasks.
• Caffeine or decaffeinated products were administered in a counterbalanced, pseudorandomized manner.

Main Results:

• Caffeine selectively reduced the 'attentional blink' in MS patients compared to placebo.
• No significant effects of caffeine were observed on choice reaction time or standard Stroop performance.
• Stroop performance showed a decline on day 7, potentially indicating caffeine withdrawal effects.

Conclusions:

• Caffeine demonstrates potential as a cognitive enhancer for attention in multiple sclerosis.
• Benefits may be most pronounced in tasks with high attentional demands, such as the RSVP dual task.
• Sustained caffeine abstinence may reveal long-term positive effects on MS-related cognition.